Human medicines European public assessment report (EPAR): Rituzena (previously Tuxella), rituximab, Lymphoma, Non-Hodgkin,Microscopic Polyangiitis,Leukemia, Lymphocytic, Chronic, B-Cell,Wegener Granulomatosis, Date of authorisation: 13/07/2017, Revision: 7, Status: Withdrawn - Withdrawal Notice | RetractBase